Get started
SAREPTA THERDRNSAREPTA THERDRNSAREPTA THERDRN

SAREPTA THERDRN

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals Bonds

S1RP34 trade ideas

Sarepta's initial breakout failed, Whats next?It looked almost certain that SRPT would break out to new highs in late June, but as the market turmoil continued the stock lost favour, seemingly the stock has now found relative support and ready for another move higher. Options markets have seen higher call buying and sentiment and speculation has also become quite bullish as the possibility of larger companies seeing SRPT as a great M&A target. Factors at Play SOURCE ZACKS Sarepta’s sole marketed drug, Exondys 51, is likely to drive its revenues higher in the second quarter of 2019. The drug has shown a strong uptrend since its launch in 2016 and is the only approved treatment for Duchenne muscular dystrophy (“DMD”) in the United States. Apart from Exondys 51, the company is developing multiple pipeline candidates, which include exon-skipping and gene therapies, for treating DMD. The company is likely to provide an update on the progress of these candidates in clinical studies. The most advanced pipeline candidate — golodirsen, an exon-skipping candidate — is under review in the United States. A decision is expected next month. The company may provide an update on its plans for the commercial launch of the candidate following a potential approval. Gene Therapy Sarepta is also focused on developing gene therapies for the treatment of central nervous system (“CNS”) disorders as well as DMD. The company is evaluating several gene therapy candidates in early- to mid-stage studies for CNS disorders and muscular dystrophy. The most advanced gene therapy candidate, LYS-SAF302 is being evaluated in a phase II/III study as a treatment for mucopolysaccharidosis Type IIIA, a progressive CNS disorder. In May, Sarepta expanded its gene therapy pipeline to six candidates by signing an agreement with the Research Institute at Nationwide Children’s Hospital. With several clinical studies underway, we expect operating expenses to increase in the soon-to-be-reported quarter. Moreover, commercial initiatives to support golodirsen potential launch will also drive expenses higher. Meanwhile, higher demand for Exondys 51 is also driving royalty payments to BioMarin BMRN. We expect to see the same trend in the to-be reported quarter.
NASDAQ:SRPTLong
by RedHotStocks
1
SAREPTA THERAPEUTICS IN BULLISH BREAKOUT In our last analysis we had identified the possibility off a breakout in SRPT, that has now come to fruition and has played out perfectly, this is a prime example of why you should analysis every company not just those highlighted on mainstream media. Such opportunities are easier to identify in larger time frames and produce mush greater gains, 24% gain in 4 days is difficult to beat. Happy investors. AVERAGE ANALYSTS PRICE TARGET $204 AVERAGE ANALYSTS RECOMMENDATION BUY P/E RATIO SHORT INTEREST 15% COMPANY PROFILE Sarepta Therapeutics , Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
NASDAQ:SRPTLong
by RedHotStocks
Sarepta Therapeutics looks like breaking out BullishSarepta is on the brink of a considerable breakout and the NASDAQ:ARRY deal yesterday has just added more fuel to the fire. Currently sitting just below the 200ma and the $128 price level,a break above looks inevitable and all indicators are very bullish with the RSI aalso breaking out. AVERAGE ANALYSTS PRICE TARGET $204 AVERAGE ANALYSTS RECOMMENDATION BUY P/E RATIO SHORT INTEREST 15% COMPANY PROFILE Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
NASDAQ:SRPTLong
by RedHotStocks